CRLNYSEServices-Commercial Physical & Biological ResearchFiscal year ends December 27
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Financials through Q2 FY2026, quarter ended Jun 27, 2026Last filing: 10-Q on Aug 5, 2026
$300.02−0.13 (-0.04%)
Close on Oct 19, 2026
- Market cap
- $14.41B
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$121.50 (+68.06%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. saw revenue fall 0.7% to $4.00B over the twelve months to Jun 27, 2026. Operating income fell 27.6% to $90.14M, moving the operating margin from 3.1% to 2.3%. Free cash flow was $370.61M, down 35.9% from a year earlier.
Revenue
$4.00B
-0.7% vs. a year earlier
Operating income
$90.14M
-27.6% vs. a year earlier
Free cash flow
$370.61M
-35.9% vs. a year earlier
EPS, diluted
-$4.91
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 27, 2026
Valuation
- Market cap
- $14.41B
- P/E ratio
- –
- Price to sales
- 3.60
- Price to book
- 5.07
- Dividend yield
- –
- Free cash flow yield
- 2.57%
Fundamentals
- Revenue
- $4.00B
- Net income
- -$238.46M
- EPS, diluted
- -$4.91
- Free cash flow
- $370.61M
- Book value per share
- $59.13
- Diluted shares
- 48M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$4.00B-0.7% YoY
Gross profit
–
Operating income
$90.14M-27.6% YoY
Net income
-$238.46M
EPS, diluted
-$4.91
Free cash flow
$370.61M-35.9% YoY
Reported periodTrailing twelve months